NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$17.60
+0.76 (+4.51%)
Close of Nov 09, 2026 · end-of-day data
NEO 8-K filings, explained
Every material Form 8-K NeoGenomics Laboratories has filed with the SEC since May 27, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NeoGenomics reported third-quarter 2026 revenue of $209 million, up 11% from a year earlier, and a GAAP net loss of $8 million, down from $27 million. The company raised its full-year 2026 revenue and adjusted EBITDA guidance and narrowed its net loss outlook, and it said CEO Tony Zook will move to Executive Chairman as Warren Stone becomes CEO on January 4, 2027.
Q3 2026 revenue was $209 million, up 11%; clinical revenue was $195 million, up 13%, with NGS revenue up 29%.
Q3 2026 GAAP net loss was $8 million, compared with $27 million in Q3 2025; adjusted EBITDA was $19 million, up 53%.
Updated FY 2026 revenue guidance is $807 million to $809 million, up from $802 million to $806 million; adjusted EBITDA guidance is approximately $60 million, up from $56 million to $58 million.
Warren Stone, currently President and COO, will become CEO and a Board member effective January 4, 2027.
NeoGenomics said its board chose President and COO Warren Stone as chief executive effective January 4, 2027, with current CEO Tony Zook becoming Executive Chairman. The company also reported preliminary, unaudited third quarter revenue of approximately $209 million and said full-year total revenue guidance is expected to increase at the midpoint, though the preliminary figures could change after quarter-end closing.
Warren Stone to become CEO effective January 4, 2027, with a base salary of $850,000 and a 100% target bonus
Preliminary Q3 2026 total revenue of approximately $209 million, with NGS revenue growth of approximately 28%
Full-year total revenue guidance expected to increase at the midpoint; adjusted EBITDA guidance reiterated from July 28, 2026
Board maximum size raised from 10 to 11 directors; Chair Lynn Tetrault steps down January 4, 2027 and will not stand for reelection in 2027
NeoGenomics said its EVP, General Counsel and Business Development, Alicia Olivo, will cease to serve as General Counsel effective September 21, 2026. She will remain an employee until October 2, 2026 for transitional purposes, and she will be eligible for separation payments and benefits under her employment agreement. The filing does not describe a financial figure for those payments or a named successor.
Alicia Olivo stops serving as General Counsel effective September 21, 2026
Olivo remains an employee until October 2, 2026 for transitional purposes
Separation payments and benefits follow Section 5(b) of her employment agreement, filed with the 10-K on February 17, 2026
The filing does not disclose a dollar amount for separation payments or a replacement
NeoGenomics reported second-quarter 2026 revenue of $202 million, up 11% from a year earlier, and GAAP net income of $2 million compared with a net loss of $45 million in the same quarter of 2025. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, which signals improved expectations for shareholders, though GAAP net income includes an $11 million gain on debt extinguishment.
Q2 2026 revenue was $202 million, up 11%; clinical services revenue rose 14% and NGS revenue rose 26%.
GAAP net income was $2 million versus a $45 million net loss a year earlier, including an $11 million gain on extinguishment of debt.
Adjusted EBITDA rose 36% to $14 million in the quarter.
Full-year 2026 revenue guidance was raised to $802 million to $806 million from $797 million to $803 million; adjusted EBITDA guidance rose to $56 million to $58 million from $55 million to $57 million.
NeoGenomics increased its Board from nine to ten directors on June 23, 2026, and appointed Carolyn S. Starrett to fill the new seat, effective immediately. Ms. Starrett previously served as CEO of Flatiron Health and as a director of Foundation Medicine, and the filing describes her as an independent director.
Board size increased from nine to ten directors on June 23, 2026
Carolyn S. Starrett appointed director, serving until the 2027 annual meeting
Starrett led Flatiron Health as CEO and Board Director from April 2021 to September 2025
Company stated her compensation follows its director compensation program in the 2026 proxy statement
NeoGenomics completed a $316.25 million offering of 0.75% convertible senior notes due 2032, including an option exercised by the initial purchasers for $41.25 million. The company also used about $263.19 million to repurchase about $276.0 million of its 0.25% convertible notes due 2028, and it used about $28.7 million of offering proceeds for capped call transactions meant to reduce potential dilution.
Notes total $316.25 million, with interest of 0.75% per year payable semiannually, maturing July 1, 2032
Initial conversion price is about $14.16 per share, a 35.0% premium to the $10.49 closing price on June 16, 2026
Up to 30,147,733 shares may be issued on conversion; the company may settle conversions in cash, shares, or both
Concurrent repurchase of about $276.0 million of 2028 notes for about $263.19 million, including accrued interest
At its May 21, 2026 annual meeting, NeoGenomics stockholders elected nine directors, approved a 5,000,000-share increase to the 2023 Equity Incentive Plan, approved an advisory vote on executive pay, and ratified Deloitte & Touche LLP as independent registered public accountant. The plan amendment increases the number of shares authorized for issuance under the plan, which the company's board had approved subject to stockholder approval.
Shares present or represented at the May 21, 2026 meeting totaled 116,630,120, about 89.61% of outstanding voting stock as of the March 23, 2026 record date.
Equity plan amendment approved with 108,010,493 votes for (97.90% of votes cast) and 2,308,922 against.
Advisory approval of named executive officer compensation received 91,781,833 votes for and 18,534,236 against.
Deloitte & Touche LLP ratified with 116,103,093 votes for and 494,869 against; all nine director nominees were elected.
NeoGenomics reported first quarter 2026 revenue of $187 million, up 11% from a year earlier, and a net loss of $17 million, down 34%. The company raised its full-year 2026 revenue guidance to $797 million-$803 million from $793 million-$801 million, while its net loss and Adjusted EBITDA guidance were unchanged.
Q1 2026 revenue was $187 million, up 11%, with Clinical revenue up 14%.
Net loss narrowed to $17 million from $26 million in Q1 2025; Adjusted EBITDA was $9 million, up 27%.
FY 2026 revenue guidance raised to $797 million-$803 million; net loss guidance of $(63) million to $(50) million and Adjusted EBITDA guidance of $55 million-$57 million were unchanged.
NeoGenomics reported fourth-quarter and full-year 2025 results on February 17, 2026, with full-year revenue up 10% to $727 million and a full-year net loss of $108 million, up 37% from 2024. The company also issued 2026 guidance calling for revenue of $793 million to $801 million and a net loss of $50 million to $63 million, which matters to shareholders because it sets the company's first public outlook for 2026.
Q4 2025 revenue rose 11% to $190 million; Q4 net loss narrowed 36% to $10 million
Full-year 2025 net loss was $108 million, up from $79 million in 2024, including $27.8 million in impairment charges
2026 guidance: revenue of $793 million to $801 million, net loss of $50 million to $63 million, adjusted EBITDA of $55 million to $57 million
The filing says the RaDaR ST patent litigation was successfully resolved
NeoGenomics said it expects preliminary, unaudited fourth-quarter 2025 revenue of about $190 million, up 11% year over year, and full-year 2025 revenue of about $727 million, up 10%. The company also announced that CFO Jeff Sherman will retire, with Abhishek Jain, formerly CFO of CareDx, becoming Chief Financial Officer on March 2, 2026. The revenue figures are not audited and may change, and the company plans to report full results on its February 2026 earnings call.
Preliminary Q4 2025 revenue of about $190 million, up 11% year over year; full-year 2025 revenue of about $727 million, up 10%
Figures are unaudited, based on management estimates, not reviewed by auditors, and subject to change
Jeff Sherman moves to Executive Vice President, Finance on March 2, 2026, retires April 14, 2026, then serves as special advisor through April 2028
Abhishek Jain to become CFO on March 2, 2026; $520,000 base salary, 60% target bonus, initial equity grant of $2,750,000
NeoGenomics said director Alison L. Hannah, MD, resigned effective December 31, 2025, and the Board appointed John P. "Jack" Kenny to fill the vacancy effective January 1, 2026. Kenny will serve until the 2026 annual meeting and will receive independent director compensation under the company's existing program. The change affects board composition but the filing does not report any financial figures.
Dr. Alison L. Hannah's resignation as director is effective December 31, 2025; the Board accepted it on December 23, 2025.
Jack Kenny was appointed to the Board effective January 1, 2026, to fill the vacancy.
Kenny previously served as President, Chief Executive Officer and Board Director of Meridian Bioscience, per the press release (Exhibit 99.1, dated December 29, 2025).
Kenny will serve until the 2026 annual meeting, and the filing reports no related-party transactions requiring disclosure under Item 404(a).
NeoGenomics reported third-quarter 2025 revenue up 12% year over year to $188 million, driven by 18% growth in clinical revenue. The net loss widened 53% to $27 million, and adjusted EBITDA fell 9% to $12.2 million, so revenue growth did not carry through to profit. The company re-affirmed its full-year 2025 guidance for revenue, net loss and adjusted EBITDA, which had been revised on July 29, 2025.
Q3 2025 consolidated revenue of $188 million, up 12%; clinical revenue up 18%, or 15% excluding the Pathline acquisition
Net loss of $27 million, up 53% from $18 million in Q3 2024; diluted loss of $0.21 per share
Q3 impairment charges of $7.1 million related to the planned sale of Trapelo; adjusted EBITDA of $12.2 million, down 9%
Full-year 2025 guidance re-affirmed: consolidated revenue $720 million to $726 million; net loss $116 million to $108 million; adjusted EBITDA $41 million to $44 million
NeoGenomics director Elizabeth Floegel gave notice on August 5, 2025 that she is resigning from the Board of Directors, effective immediately. The company said her decision did not stem from any disagreement with it on operations, policies or practices.
Director Elizabeth Floegel resigned from the Board of Directors, effective immediately
Resignation notice was provided to the company on August 5, 2025
Company states no disagreement on operations, policies or practices led to the resignation
Filing dated August 8, 2025, signed by EVP, General Counsel and Corporate Secretary Alicia C. Olivo
NeoGenomics reported second-quarter 2025 revenue of $181 million, up 10% from a year earlier, but its net loss widened to $45 million, including $20 million of impairment charges. The company also lowered its full-year 2025 revenue guidance to $720 million to $726 million from $747 million to $759 million, and widened its expected net loss, which matters to shareholders because it signals weaker results than previously expected.
Q2 2025 revenue rose 10% to $181 million; clinical revenue grew 16%, or 13% excluding Pathline
Q2 net loss increased 142% to $45 million, including $20 million of impairment charges; Adjusted EBITDA was $10.7 million, flat year over year
2025 revenue guidance lowered to $720 million-$726 million from $747 million-$759 million
2025 GAAP net loss guidance widened to $(116) million-$(108) million from $(85) million-$(77) million
NeoGenomics expanded its board from nine to ten members on June 19, 2025, and appointed Marjorie C. Green to fill the new seat. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. The filing reports no financial results or changes to guidance, so the appointment is the only shareholder-relevant event disclosed.
Board size increased from nine to ten members; Green appointed June 19, 2025
Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck
Previously held roles at Seagen and Genentech, per the press release
Will serve until the 2026 annual meeting of stockholders or earlier resignation or removal
At its May 22, 2025 annual meeting, NeoGenomics stockholders approved an amendment adding 4,325,000 shares to the 2023 Equity Incentive Plan, along with a one-year minimum vesting period and limits on share recycling. Stockholders also re-elected nine directors, approved executive pay on an advisory basis, and ratified Deloitte & Touche LLP as auditor.
Stockholders approved adding 4,325,000 shares to the 2023 Equity Incentive Plan, with 94.90% of votes cast in favor.
Amendment sets a one-year minimum vesting period for awards and prohibits re-use of shares withheld for taxes and net share counting on option exercises.
Board will hold advisory votes on named executive compensation every year, after 103,435,850 votes favored annual frequency.
Deloitte & Touche LLP was ratified as independent registered public accountant with 112,929,861 votes for (99.86% of votes cast).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NeoGenomics Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →